126 related articles for article (PubMed ID: 37923625)
21. Imaging features of fumarate hydratase-deficient renal cell carcinomas: a retrospective study.
Nikolovski I; Carlo MI; Chen YB; Vargas HA
Cancer Imaging; 2021 Feb; 21(1):24. PubMed ID: 33608050
[TBL] [Abstract][Full Text] [Related]
22. Cascade Fumarate Hydratase mutation screening allows early detection of kidney tumour: a case report.
Chan MMY; Barnicoat A; Mumtaz F; Aitchison M; Side L; Brittain H; Bates AWH; Gale DP
BMC Med Genet; 2017 Jul; 18(1):79. PubMed ID: 28747166
[TBL] [Abstract][Full Text] [Related]
23. Low-Grade Fumarate Hydratase-Deficient Renal Cell Carcinoma in a 30-Year-Old Female.
Wyvekens N; Anderson WJ; Kim YX; Carter M; Hirsch MS
Int J Surg Pathol; 2022 Apr; 30(2):184-189. PubMed ID: 34180725
[TBL] [Abstract][Full Text] [Related]
24. Tubulocystic Carcinoma of the Kidney With Poorly Differentiated Foci: A Frequent Morphologic Pattern of Fumarate Hydratase-deficient Renal Cell Carcinoma.
Smith SC; Trpkov K; Chen YB; Mehra R; Sirohi D; Ohe C; Cani AK; Hovelson DH; Omata K; McHugh JB; Jochum W; Colecchia M; Amin M; Divatia MK; Hes O; Menon S; Werneck da Cunha I; Tripodi S; Brimo F; Gill AJ; Osunkoya AO; Magi-Galluzzi C; Sibony M; Williamson SR; Nesi G; Picken MM; Maclean F; Agaimy A; Cheng L; Epstein JI; Reuter VE; Tickoo SK; Tomlins SA; Amin MB
Am J Surg Pathol; 2016 Nov; 40(11):1457-1472. PubMed ID: 27635946
[TBL] [Abstract][Full Text] [Related]
25. Advanced fumarate hydratase-deficient renal cell carcinoma responding to combination immune checkpoint inhibitors.
Howells E; Wigston L; Mackie G; Tran B; Nott L
Can J Urol; 2023 Jun; 30(3):11558-11561. PubMed ID: 37344468
[TBL] [Abstract][Full Text] [Related]
26. [FH (Fumarate Hydratase)-deficient renal cell carcinoma: A case report].
Allaume P; Kammerer-Jacquet SF; Papadopoulos S; Rioux-Leclercq N
Ann Pathol; 2023 Sep; 43(5):417-420. PubMed ID: 36822902
[TBL] [Abstract][Full Text] [Related]
27. AKR1B10 Is a New Sensitive and Specific Marker for Fumarate Hydratase-Deficient Renal Cell Carcinoma.
Zheng L; Zhang X; Pan X; Huang Z; Zhang M; Xian J; Wei Y; Nie L; Zhang M; Gong J; Chen X; Zhou Q; Zeng H; Chen N
Mod Pathol; 2023 Nov; 36(11):100303. PubMed ID: 37580017
[TBL] [Abstract][Full Text] [Related]
28. Circulating succinate-modifying metabolites accurately classify and reflect the status of fumarate hydratase-deficient renal cell carcinoma.
Zheng L; Zhu ZR; Sneh T; Zhang WT; Wang ZY; Wu GY; He W; Qi HG; Wang H; Wu XY; Fernández-García J; Abramovich I; Xu YZ; Zhang J; Gottlieb E
J Clin Invest; 2023 Jun; 133(11):. PubMed ID: 37053010
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive Molecular Characterization and Response to Therapy in Fumarate Hydratase-Deficient Renal Cell Carcinoma.
Gleeson JP; Nikolovski I; Dinatale R; Zucker M; Knezevic A; Patil S; Ged Y; Kotecha RR; Shapnik N; Murray S; Russo P; Coleman J; Lee CH; Stadler ZK; Hakimi AA; Feldman DR; Motzer RJ; Reznik E; Voss MH; Chen YB; Carlo MI
Clin Cancer Res; 2021 May; 27(10):2910-2919. PubMed ID: 33658299
[TBL] [Abstract][Full Text] [Related]
30. Characterization of protein S-(2-succino)-cysteine (2SC) succination as a biomarker for fumarate hydratase-deficient renal cell carcinoma.
Mannan R; Wang X; Bawa PS; Chugh S; Chinnaiyan AK; Rangaswamy R; Zhang Y; Cao X; Smith SC; Trpkov K; Williamson SR; Sangoi AR; Mohanty S; McKenney JK; Gupta S; Magi-Galluzzi C; Argani P; Osunkoya AO; Chinnaiyan AM; Dhanasekaran SM; Mehra R
Hum Pathol; 2023 Apr; 134():102-113. PubMed ID: 36581128
[TBL] [Abstract][Full Text] [Related]
31. GATA3 aids in distinguishing fumarate hydratase-deficient renal cell carcinoma from papillary renal cell carcinoma.
Liu Y; Dong Y; Gu Y; Xu H; Fan Y; Li X; Dong L; Zhou L; Yang X; Wang C
Ann Diagn Pathol; 2022 Oct; 60():152007. PubMed ID: 35841867
[TBL] [Abstract][Full Text] [Related]
32. Fumarate hydratase-deficient renal cell carcinoma: a case report and review of the literature.
Lv Y; Song L; Hu M
J Med Case Rep; 2023 Apr; 17(1):182. PubMed ID: 37076922
[TBL] [Abstract][Full Text] [Related]
33. Radical nephrectomy and regional lymph node dissection for locally advanced type 2 papillary renal cell carcinoma in an at-risk individual from a family with hereditary leiomyomatosis and renal cell cancer: a case report.
Kamai T; Abe H; Arai K; Murakami S; Sakamoto S; Kaji Y; Yoshida KI
BMC Cancer; 2016 Mar; 16():232. PubMed ID: 26983443
[TBL] [Abstract][Full Text] [Related]
34. Fumarate hydratase as a therapeutic target in renal cancer.
Kancherla P; Daneshvar M; Sager RA; Mollapour M; Bratslavsky G
Expert Opin Ther Targets; 2020 Sep; 24(9):923-936. PubMed ID: 32744123
[TBL] [Abstract][Full Text] [Related]
35. Re-evaluation of 33 'unclassified' eosinophilic renal cell carcinomas in young patients.
Li Y; Reuter VE; Matoso A; Netto GJ; Epstein JI; Argani P
Histopathology; 2018 Mar; 72(4):588-600. PubMed ID: 28898443
[TBL] [Abstract][Full Text] [Related]
36. Hereditary Leiomyomatosis and Renal Cell Cancer: Clinical, Molecular, and Screening Features in a Cohort of 185 Affected Individuals.
Forde C; Lim DHK; Alwan Y; Burghel G; Butland L; Cleaver R; Dixit A; Evans DG; Hanson H; Lalloo F; Oliveira P; Vialard L; Wallis Y; Maher ER; Woodward ER
Eur Urol Oncol; 2020 Dec; 3(6):764-772. PubMed ID: 31831373
[TBL] [Abstract][Full Text] [Related]
37. Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma.
Xu Y; Kong W; Cao M; Wang J; Wang Z; Zheng L; Wu X; Cheng R; He W; Yang B; Dong B; Pan J; Chen Y; Huang J; Jiang C; Zhai W; Li F; Chen R; Zhou X; Wu G; Geng X; Chen J; An H; Yuan Y; Xu T; Chen D; Lin D; Xu L; Huang K; Peng L; Yu Y; Tai S; Qi H; Luo K; Kang X; Wang H; Huang Y; Zhang J; Xue W
Eur Urol; 2023 Feb; 83(2):163-172. PubMed ID: 35715365
[TBL] [Abstract][Full Text] [Related]
38. Reassessing the clinical spectrum associated with hereditary leiomyomatosis and renal cell carcinoma syndrome in French FH mutation carriers.
Muller M; Ferlicot S; Guillaud-Bataille M; Le Teuff G; Genestie C; Deveaux S; Slama A; Poulalhon N; Escudier B; Albiges L; Soufir N; Avril MF; Gardie B; Saldana C; Allory Y; Gimenez-Roqueplo AP; Bressac-de Paillerets B; Richard S; Benusiglio PR
Clin Genet; 2017 Dec; 92(6):606-615. PubMed ID: 28300276
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of fumarate hydratase is related to tumorigenesis in sporadic renal cell cancer.
Ha YS; Chihara Y; Yoon HY; Kim YJ; Kim TH; Woo SH; Yun SJ; Kim IY; Hirao Y; Kim WJ
Urol Int; 2013; 90(2):233-9. PubMed ID: 23295344
[TBL] [Abstract][Full Text] [Related]
40. Programmed death-1 (PD-1) receptor/PD-1 ligand (PD-L1) expression in fumarate hydratase-deficient renal cell carcinoma.
Alaghehbandan R; Stehlik J; Trpkov K; Magi-Galluzzi C; Condom Mundo E; Pane Foix M; Berney D; Sibony M; Suster S; Agaimy A; Montiel DP; Pivovarcikova K; Michalova K; Daum O; Ondic O; Rotterova P; Dusek M; Hora M; Michal M; Hes O
Ann Diagn Pathol; 2017 Aug; 29():17-22. PubMed ID: 28807336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
